Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of vatalanib monotherapy in second-line advanced non-small cell lung cancer
2004-002290-22Phase 2Completed
- Sponsor
- Schering AG
- Start
- Jun 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vatalanib in non-small cell lung cancer (NSCLC), sponsored by Schering AG. Primary endpoint: Objective response rate at 12 weeks. Started Jun 2005; status: completed.
02
Drugs
vatalanib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2004-002290-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002290-22.